Endocyte Inc. (ECYT) and Merck (MRK) announced Monday morning that they have entered into an agreement to develop and commercialize Endocyte's investigational therapeutic candidate, vintafolide. Merck, through a subsidiary, will gain worldwide rights to develop and commercialize vintafolide. Endocyte will receive a $120 million upfront payment and is eligible for milestone payments of up to $880 million.
Endocyte has gapped open sharply higher Monday and is now up 4.05 at $7.85 on above average volume. The stock has jumped to a 4-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.